Based on these differences, NOD1 inhibition might serve as a therapeutic option to alleviate obesity-induced glucose intolerance, while NOD2 stimulation might favor blood glucose homeostasis. The gene discussed is NOD1; the disease is obesity due to melanocortin 4 receptor deficiency.